EP0474727B1
(de)
*
|
1989-05-19 |
1997-07-23 |
Genentech, Inc. |
Her2 extrazellulare domäne
|
US5183884A
(en)
*
|
1989-12-01 |
1993-02-02 |
United States Of America |
Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
|
US5578482A
(en)
*
|
1990-05-25 |
1996-11-26 |
Georgetown University |
Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
|
US5776755A
(en)
*
|
1992-10-09 |
1998-07-07 |
Helsinki University Licensing, Ltd. |
FLT4, a receptor tyrosine kinase
|
US6107046A
(en)
*
|
1992-10-09 |
2000-08-22 |
Orion Corporation |
Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
|
US6824777B1
(en)
*
|
1992-10-09 |
2004-11-30 |
Licentia Ltd. |
Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
|
US5811098A
(en)
*
|
1992-11-24 |
1998-09-22 |
Bristol-Myers Squibb Company |
Antibodies to HER4, human receptor tyrosine kinase
|
US6051221A
(en)
*
|
1993-07-09 |
2000-04-18 |
Glaxo Wellcome Inc. |
BRK protein tyrosine kinase and encoding nucleic acid
|
DE69435103D1
(de)
*
|
1993-10-27 |
2008-07-10 |
Univ Columbia |
Methode zur Bildung einer subtrahierten cDNA Bank und ihre Verwendung
|
US5518885A
(en)
*
|
1994-04-19 |
1996-05-21 |
The United States Of America As Represented By The Department Of Health & Human Services |
ERBB2 promoter binding protein in neoplastic disease
|
US7175995B1
(en)
|
1994-10-27 |
2007-02-13 |
Thomas Jefferson University |
TCL-1 protein and related methods
|
US5985598A
(en)
*
|
1994-10-27 |
1999-11-16 |
Thomas Jefferson University |
TCL-1 gene and protein and related methods and compositions
|
US5635351A
(en)
*
|
1995-03-14 |
1997-06-03 |
The Regents Of The University Of California |
Genetic gain and loss in gliomas
|
US6685940B2
(en)
*
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
US6267958B1
(en)
*
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US5968511A
(en)
|
1996-03-27 |
1999-10-19 |
Genentech, Inc. |
ErbB3 antibodies
|
JP3925943B2
(ja)
*
|
1996-03-27 |
2007-06-06 |
ジェネンテック インコーポレーテッド |
ErbB3抗体
|
DK0912734T3
(da)
|
1996-07-12 |
2011-02-07 |
Genentech Inc |
Kimæriske heteromultimer-adhæsiner
|
CA2257839C
(en)
*
|
1996-07-12 |
2012-10-23 |
Genentech, Inc. |
Gamma-heregulin
|
US5710137A
(en)
|
1996-08-16 |
1998-01-20 |
The Trustees Of Columbia University In The City Of New York |
Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype
|
US7371376B1
(en)
|
1996-10-18 |
2008-05-13 |
Genentech, Inc. |
Anti-ErbB2 antibodies
|
AU732027B2
(en)
*
|
1997-02-10 |
2001-04-12 |
Genentech Inc. |
Heregulin variants
|
US6136558A
(en)
*
|
1997-02-10 |
2000-10-24 |
Genentech, Inc. |
Heregulin variants
|
AU7267398A
(en)
*
|
1997-04-30 |
1998-11-24 |
Hans Klingemann |
Natural killer cell lines and methods of use
|
US7052692B1
(en)
|
1997-09-02 |
2006-05-30 |
Advanced Research & Technology Institute |
Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression
|
ES2316173T3
(es)
|
1997-10-29 |
2009-04-01 |
Genentech, Inc. |
Genes inducibles por wnt-1.
|
EP1027437B8
(de)
|
1997-10-29 |
2008-10-29 |
Genentech, Inc. |
Verwendung des wnt-1 induzierten sekretierten polypeptids wisp-1
|
ZA9811162B
(en)
*
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
US20010023241A1
(en)
*
|
1998-02-04 |
2001-09-20 |
Sliwkowski Mark X. |
Use of heregulin as a growth factor
|
EP1941905A1
(de)
|
1998-03-27 |
2008-07-09 |
Genentech, Inc. |
APO-2 Liganden-Anti-HER-2-Antikörper-Synergismus
|
DE69942981D1
(de)
*
|
1998-10-09 |
2011-01-05 |
Vegenics Ltd |
Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie
|
ATE397959T1
(de)
*
|
1999-04-06 |
2008-07-15 |
Genentech Inc |
Verwendung von erbb-rezeptorliganden zur behandlung von diabetes
|
AUPQ105799A0
(en)
*
|
1999-06-18 |
1999-07-08 |
Victor Chang Cardiac Research Institute, The |
Cell growth inhibition
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
DK1189634T3
(da)
*
|
1999-06-25 |
2007-06-25 |
Genentech Inc |
Behandling af prostatacancer med anti-ErbB2-antistoffer
|
US6949245B1
(en)
*
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
EP1191944A2
(de)
|
1999-06-25 |
2002-04-03 |
Genentech, Inc. |
Methoden zur behandlung unter verwendung von erb antibody-mayntasinoid konjugate
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
KR100797308B1
(ko)
|
1999-06-25 |
2008-01-23 |
제넨테크, 인크. |
인간화 항-ErbB2 항체 및 항-ErbB2 항체를 사용한치료 방법
|
ES2330301T3
(es)
*
|
1999-08-27 |
2009-12-09 |
Genentech, Inc. |
Dosificaciones para tratamiento con anticuerpos anti-erbb2.
|
US7892541B1
(en)
|
1999-09-30 |
2011-02-22 |
Tumor Biology Investment Group, Inc. |
Soluble epidermal growth factor receptor isoforms
|
US7390632B2
(en)
*
|
1999-09-30 |
2008-06-24 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 receptor isoforms
|
EP2266607A3
(de)
|
1999-10-01 |
2011-04-20 |
Immunogen, Inc. |
Immunokonjugate für Krebsbehandlung
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
HUP0300369A2
(hu)
|
2000-04-11 |
2003-06-28 |
Genentech, Inc. |
Többértékű antitestek és alkalmazásuk
|
WO2001083781A2
(en)
*
|
2000-04-28 |
2001-11-08 |
Millennium Pharmaceuticals, Inc. |
14094, a novel human trypsin family member and uses thereof
|
NZ522444A
(en)
|
2000-05-19 |
2004-09-24 |
Genentech Inc |
Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
|
CN1204142C
(zh)
*
|
2000-06-01 |
2005-06-01 |
冯宝章 |
反基因V-erbB寡核苷酸及其应用
|
US6277640B1
(en)
|
2000-07-31 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of Her-3 expression
|
US20020119148A1
(en)
*
|
2000-09-01 |
2002-08-29 |
Gerritsen Mary E. |
ErbB4 antagonists
|
WO2002039121A2
(en)
*
|
2000-11-03 |
2002-05-16 |
Board Of Regents, The University Of Texas System |
Methods for detecting the efficacy of anticancer treatments
|
CA2435503C
(en)
*
|
2001-01-19 |
2011-02-22 |
Ludwig Institute For Cancer Research |
Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
|
EP1228766A1
(de)
*
|
2001-01-31 |
2002-08-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
PYK2 Phosphorylierung durch HER3 induziert Tumorinvasion
|
US7638598B2
(en)
|
2001-04-06 |
2009-12-29 |
The Trustees Of The University Of Pennsylvania |
ErbB interface peptidomimetics and methods of use thereof
|
WO2002088363A2
(en)
*
|
2001-05-02 |
2002-11-07 |
Bayer Healthcare Ag |
Regulation of novel human prolyl 4-hydroxylases
|
US7744882B2
(en)
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 methods of detection and antibodies
|
US7612042B2
(en)
|
2001-05-31 |
2009-11-03 |
Tumor Biology Investment Group, Inc. |
Methods for inhibiting heregulin and treating cancer
|
US7745398B2
(en)
*
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 and treatment of cancer
|
DE10131187C2
(de)
*
|
2001-06-28 |
2003-06-18 |
Infineon Technologies Ag |
Belichtungsmaske mit reparierter Blindstruktur
|
WO2003011897A1
(en)
*
|
2001-07-27 |
2003-02-13 |
The Regents Of The University Of California |
Modulation of heregulin and her3 interaction
|
EP1283053A1
(de)
|
2001-08-09 |
2003-02-12 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Inhibitore der HER3 Aktivität
|
WO2003025130A2
(en)
*
|
2001-09-14 |
2003-03-27 |
Incyte Genomics, Inc. |
Receptors and membrane-associated proteins
|
JP2003110360A
(ja)
*
|
2001-09-28 |
2003-04-11 |
Seiko Epson Corp |
電圧制御型発振器、受信装置および通信装置
|
AU2003218600C1
(en)
*
|
2002-03-26 |
2009-12-17 |
Zensun (Shanghai) Science & Technology Co., Ltd. |
ERBB3 based methods and compositions for treating neoplasms
|
US7402397B2
(en)
|
2002-05-21 |
2008-07-22 |
Monogram Biosciences, Inc. |
Detecting and profiling molecular complexes
|
US20040229380A1
(en)
*
|
2002-05-21 |
2004-11-18 |
Po-Ying Chan-Hui |
ErbB heterodimers as biomarkers
|
US20040229294A1
(en)
*
|
2002-05-21 |
2004-11-18 |
Po-Ying Chan-Hui |
ErbB surface receptor complexes as biomarkers
|
CA2490542C
(en)
|
2002-05-23 |
2013-07-16 |
Mark I. Greene |
Fas peptide mimetics and uses thereof
|
BR0312534A
(pt)
*
|
2002-07-15 |
2007-03-13 |
Genentech Inc |
método de identificação de um tumor, método para a identificação de células de tumor, método para prever a resposta de um indivìduo diagnosticado com um tumor de her2-positivo, método para a identificação de um individuo responsivo ao tratamento com anticorpo anti-her2 e métodos de tratamento de um paciente e artigo de manufatura
|
US8505468B2
(en)
*
|
2002-11-19 |
2013-08-13 |
Sharp Kabushiki Kaisha |
Substrate accommodating tray
|
JP2006516117A
(ja)
*
|
2002-11-21 |
2006-06-22 |
ジェネンテック・インコーポレーテッド |
抗ErbB2抗体を用いた非悪性疾病または疾患の治療
|
JP2006521821A
(ja)
|
2003-04-01 |
2006-09-28 |
モノグラム バイオサイエンシズ,インコーポレーテッド |
バイオマーカーとしての表面受容体複合体
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
US20050239088A1
(en)
*
|
2003-05-16 |
2005-10-27 |
Shepard H M |
Intron fusion proteins, and methods of identifying and using same
|
US7402398B2
(en)
*
|
2003-07-17 |
2008-07-22 |
Monogram Biosciences, Inc. |
Measuring receptor homodimerization
|
BRPI0413471A
(pt)
*
|
2003-08-11 |
2006-10-17 |
Monogram Biosciences Inc |
métodos para detectar um ou mais complexos de proteìnas e para detectar um complexo em uma amostra biológica
|
US7402399B2
(en)
*
|
2003-10-14 |
2008-07-22 |
Monogram Biosciences, Inc. |
Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
|
SG195524A1
(en)
|
2003-11-06 |
2013-12-30 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
JP4969440B2
(ja)
*
|
2004-04-08 |
2012-07-04 |
デビッド, ビー. エイガス, |
疼痛治療のためのErbBアンタゴニスト
|
EP1745073A2
(de)
*
|
2004-05-14 |
2007-01-24 |
Receptor Biologix, Inc. |
Isoformen eines zelloberflächenrezeptors und verfahren zu deren identifizierung und anwendung
|
KR20120064120A
(ko)
|
2004-06-01 |
2012-06-18 |
제넨테크, 인크. |
항체 약물 접합체 및 방법
|
GT200500155A
(es)
*
|
2004-06-16 |
2006-05-15 |
|
Terapia del càncer resistente al platino
|
ZA200701234B
(en)
*
|
2004-07-22 |
2008-12-31 |
Genentech Inc |
HER2 antibody composition
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
SI1791565T1
(sl)
|
2004-09-23 |
2016-08-31 |
Genentech, Inc. |
Cisteinsko konstruirana protitelesa in konjugati
|
JO3000B1
(ar)
*
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US7939267B2
(en)
*
|
2004-11-04 |
2011-05-10 |
Laboratory Corporation Of America Holdings |
Detection of activation of endothelial cells as surrogate marker for angiogenesis
|
WO2006063042A2
(en)
*
|
2004-12-07 |
2006-06-15 |
Genentech, Inc. |
Selecting patients for therapy with a her inhibitor
|
EP3698807A1
(de)
|
2005-01-21 |
2020-08-26 |
Genentech, Inc. |
Fixe dosierung von her-antikörpern
|
JP2008530123A
(ja)
*
|
2005-02-09 |
2008-08-07 |
ジェネンテック・インコーポレーテッド |
マトリックスメタロプロテアーゼアンタゴニストを用いたher2のシェディングの阻害
|
EP2399605A1
(de)
*
|
2005-02-23 |
2011-12-28 |
Genentech, Inc. |
Ausdehnungszeit einer Krankheitsprogression oder -überlebens bei Krebspatienten
|
TW200642695A
(en)
*
|
2005-03-08 |
2006-12-16 |
Genentech Inc |
Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Herceptin(登録商標)補助療法
|
US20090170769A1
(en)
*
|
2005-05-13 |
2009-07-02 |
Pei Jin |
Cell surface receptor isoforms and methods of identifying and using the same
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
EP2054444B1
(de)
|
2006-08-04 |
2016-11-02 |
MedImmune Limited |
Antikörper gegen erbb2
|
CA2670522C
(en)
|
2006-11-28 |
2018-08-07 |
U3 Pharma Gmbh |
Activated her3 as a marker for predicting therapeutic efficacy
|
EP2129396B1
(de)
|
2007-02-16 |
2013-08-21 |
Merrimack Pharmaceuticals, Inc. |
Antikörper gegen erbb3 und ihre verwendung
|
JP2010520225A
(ja)
|
2007-03-02 |
2010-06-10 |
ジェネンテック, インコーポレイテッド |
低her3発現に基づくher二量化インヒビターに対する応答を予測する方法
|
JP5779350B2
(ja)
|
2007-03-27 |
2015-09-16 |
シー レーン バイオテクノロジーズ, エルエルシー |
抗体代替軽鎖配列を含む構築物およびライブラリー
|
SI2171090T1
(sl)
|
2007-06-08 |
2013-07-31 |
Genentech, Inc. |
Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje
|
WO2009070772A1
(en)
*
|
2007-11-27 |
2009-06-04 |
Monogram Biosciences, Inc. |
Enhanced method for detecting and/or quantifying an analyte in a sample
|
CA2711843C
(en)
*
|
2007-12-20 |
2018-11-13 |
Laboratory Corporation Of America Holdings |
Her-2 diagnostic methods
|
CA2711737C
(en)
|
2008-01-18 |
2015-03-31 |
Natco Pharma Limited |
6,7-dialkoxy quinazoline derivatives useful for treatment of cancer related disorders
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
NZ602675A
(en)
|
2008-03-18 |
2014-03-28 |
Genentech Inc |
Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
WO2009157919A1
(en)
*
|
2008-06-23 |
2009-12-30 |
Tumor Biology Investment Group, Inc. |
SOLUBLE ErbB3 DETECTION, REGULATION AND TREATMENT OF CANCER
|
PE20120015A1
(es)
*
|
2008-08-15 |
2012-01-26 |
Merrimack Pharmaceuticals Inc |
Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico
|
CA2764386C
(en)
|
2008-12-01 |
2018-05-01 |
Laboratory Corporation Of America Holdings |
P95-her2 antibodies and uses thereof
|
US20120295259A1
(en)
|
2011-05-19 |
2012-11-22 |
Laboratory Corporation Of America Holdings |
Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients
|
SG172983A1
(en)
*
|
2009-01-15 |
2011-08-29 |
Lab Corp America Holdings |
Methods of determining patient response by measurement of her-3
|
SG174378A1
(en)
*
|
2009-03-20 |
2011-10-28 |
Genentech Inc |
Bispecific anti-her antibodies
|
US8362215B2
(en)
*
|
2009-04-29 |
2013-01-29 |
Trellis Bioscience, Llc |
Antibodies immunoreactive with heregulin-coupled HER3
|
CA2761681A1
(en)
|
2009-05-13 |
2010-11-18 |
Sea Lane Biotechnologies, Llc |
Neutralizing molecules to influenza viruses
|
US20120121586A1
(en)
|
2009-05-29 |
2012-05-17 |
Astrid Kiermaier |
Modulators for her2 signaling in her2 expressing patients with gastric cancer
|
US9050341B2
(en)
|
2009-07-14 |
2015-06-09 |
Natco Pharma Limited |
Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
|
AU2010306774A1
(en)
|
2009-10-14 |
2012-05-03 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents targeting IGF-1R and ErbB3 signalling and uses thereof
|
EP2896632B1
(de)
|
2009-11-13 |
2017-10-25 |
Daiichi Sankyo Europe GmbH |
Material und Verfahren zur Behandlung oder Vorbeugung von HER-3-assoziierten Erkrankungen
|
RU2016105962A
(ru)
|
2009-12-04 |
2018-11-23 |
Дженентек, Инк. |
Мультиспецифические антитела, аналоги антител, композиции и способы
|
HUE029026T2
(en)
|
2009-12-22 |
2017-01-30 |
Roche Glycart Ag |
Anti-HER3 antibodies and their applications
|
PL2544680T3
(pl)
|
2010-03-11 |
2015-08-31 |
Merrimack Pharmaceuticals Inc |
Zastosowanie inhibitorów ERBB1 w leczeniu potrójnie ujemnego raka gruczołu sutkowego
|
SG184452A1
(en)
|
2010-04-09 |
2012-11-29 |
Aveo Pharmaceuticals Inc |
Anti-erbb3 antibodies
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
US8741288B2
(en)
*
|
2010-07-07 |
2014-06-03 |
Chang Gung Medical Foundation, Linkou Branch |
Protein markers for detecting liver cancer and method for identifying the markers thereof
|
PE20140230A1
(es)
|
2010-08-20 |
2014-02-26 |
Novartis Ag |
Anticuerpos para el receptor del factor de crecimiento epidermico 3(her3)
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
MX2013010379A
(es)
|
2011-03-11 |
2014-03-27 |
Merrimack Pharmaceuticals Inc |
Uso de inhibidores de receptores de la familia egfr en el tratamiento de canceres de mama refractarios a hormonas.
|
KR20140138353A
(ko)
|
2011-04-19 |
2014-12-03 |
메리맥 파마슈티컬즈, 인크. |
단일특이적 및 이중특이적 항-igf-1r 및 항 erbb3 항체
|
WO2012156309A1
(en)
|
2011-05-13 |
2012-11-22 |
Millegen |
Antibodies against her3
|
CN103781800A
(zh)
|
2011-06-20 |
2014-05-07 |
协和发酵麒麟株式会社 |
抗erbB3抗体
|
CA2842860A1
(en)
|
2011-07-28 |
2013-01-31 |
Sea Lane Biotechnologies, Llc |
Sur-binding proteins
|
WO2013033380A1
(en)
|
2011-08-31 |
2013-03-07 |
Genentech, Inc. |
Diagnostic markers
|
US9273143B2
(en)
|
2011-09-30 |
2016-03-01 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
|
IN2014CN03042A
(de)
|
2011-09-30 |
2015-07-03 |
Regeneron Pharma |
|
AU2012318541B2
(en)
|
2011-10-06 |
2018-04-12 |
Aveo Pharmaceuticals, Inc. |
Predicting tumor response to anti-ERBB3 antibodies
|
PL2766040T3
(pl)
|
2011-10-14 |
2019-11-29 |
Hoffmann La Roche |
Pertuzumab, trastuzumab, docetaksel i karboplatyna w leczeniu wczesnego stadium raka piersi
|
EP3608340A1
(de)
|
2011-11-23 |
2020-02-12 |
Medlmmune, LLC |
Her3-spezifische bindungsmoleküle und verwendungen davon
|
CN104271761B
(zh)
|
2011-11-30 |
2017-03-15 |
霍夫曼-拉罗奇有限公司 |
癌症中的erbb3突变
|
UY34487A
(es)
|
2011-12-05 |
2013-07-31 |
Novartis Ag |
Anticuerpos para receptor de factor de crecimiento epidérmico 3(her3)
|
TW201328707A
(zh)
|
2011-12-05 |
2013-07-16 |
Novartis Ag |
針對表皮生長因子受體3(her3)之區域ii之her3抗體
|
EP2788500A1
(de)
|
2011-12-09 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Identifizierung von non-respondern auf her2-inhibitoren
|
CA2859744A1
(en)
|
2011-12-22 |
2013-06-27 |
Sea Lane Biotechnologies, Llc |
Surrogate binding proteins
|
EP2817340B1
(de)
|
2012-02-23 |
2020-12-09 |
Daiichi Sankyo Europe GmbH |
Her3 inhibitor zur modulierung der radiosensitivität
|
SG11201406079TA
(en)
|
2012-03-27 |
2014-10-30 |
Genentech Inc |
Diagnosis and treatments relating to her3 inhibitors
|
CN104684579A
(zh)
|
2012-04-02 |
2015-06-03 |
梅里麦克制药股份有限公司 |
单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用
|
KR102291355B1
(ko)
|
2012-11-30 |
2021-08-19 |
에프. 호프만-라 로슈 아게 |
Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
|
US9180185B2
(en)
|
2013-01-11 |
2015-11-10 |
Hoffman-La Roche Inc. |
Combination therapy of anti-HER3 antibodies
|
WO2014122582A1
(en)
|
2013-02-05 |
2014-08-14 |
Nestec S.A. |
Drug selection for non-small cell lung cancer therapy
|
MY170528A
(en)
|
2013-02-18 |
2019-08-09 |
Vegenics Pty Ltd |
Vegfr-3 ligand binding molecules and uses thereof
|
CN105264382A
(zh)
|
2013-04-05 |
2016-01-20 |
美国控股实验室公司 |
基于检测her3活化辅助癌症的诊断、预后和治疗的系统和方法
|
AU2014262566A1
(en)
|
2013-05-08 |
2015-11-12 |
Zymeworks Inc. |
Bispecific HER2 and HER3 antigen binding constructs
|
US11305012B2
(en)
|
2013-09-24 |
2022-04-19 |
Medimmune, Llc |
Binding molecules specific for HER3 and uses thereof
|
WO2015100459A2
(en)
|
2013-12-27 |
2015-07-02 |
Merrimack Pharmaceuticals, Inc. |
Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
|
EP3122900A1
(de)
|
2014-03-24 |
2017-02-01 |
F. Hoffmann-La Roche AG |
Krebsbehandlung mit c-met-antagonisten und korrelation desselben mit hgf-expression
|
EP3789042A1
(de)
|
2014-04-10 |
2021-03-10 |
Daiichi Sankyo Company, Limited |
Verfahren zur herstellung von anti-her3-antikörper-arzneimittel-konjugat
|
WO2015157634A1
(en)
|
2014-04-11 |
2015-10-15 |
Kolltan Pharmaceuticals, Inc. |
Anti-erbb antibodies and methods of use thereof
|
US20170291956A1
(en)
|
2014-07-16 |
2017-10-12 |
David Livingston |
HER3 Inhibition in Low-grade Serous Ovarian Cancers
|
WO2017014810A1
(en)
*
|
2015-07-17 |
2017-01-26 |
Czerniecki Brian J |
Identification of immunogenic mhc class ii peptides for immune-based therapy
|
WO2016011432A2
(en)
|
2014-07-17 |
2016-01-21 |
Czerniecki Brian J |
Identification of immunogenic mhc class ii peptides for immune-based therapy
|
CN108367003B
(zh)
|
2014-12-12 |
2022-01-21 |
麻省总医院 |
乳腺癌脑转移的治疗
|
EP3303398A1
(de)
|
2015-05-29 |
2018-04-11 |
Merrimack Pharmaceuticals, Inc. |
Kombinationskrebstherapien
|
US10184006B2
(en)
|
2015-06-04 |
2019-01-22 |
Merrimack Pharmaceuticals, Inc. |
Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
|
KR20180021723A
(ko)
|
2015-06-29 |
2018-03-05 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트의 선택적 제조 방법
|
US20170233491A1
(en)
|
2016-01-19 |
2017-08-17 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of combination therapies comprising istiratumab, uses and methods of treatment
|
EP3429623A1
(de)
|
2016-03-15 |
2019-01-23 |
Merrimack Pharmaceuticals, Inc. |
Verfahren zur behandlung von er+, her2-, hrg+ brustkrebs mithilfe von kombinationstherapien mit einem anti-erbb3-antikörper
|
US20190151346A1
(en)
|
2016-05-10 |
2019-05-23 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
EP3552626A4
(de)
|
2016-12-12 |
2020-06-10 |
Daiichi Sankyo Company, Limited |
Kombination aus antikörper-wirkstoff-konjugat und immun-checkpoint-inhibitor
|
MX2019007801A
(es)
|
2016-12-28 |
2019-10-30 |
Genentech Inc |
Tratamiento de cáncer avanzado con expresión de her2.
|
EP3570884B1
(de)
|
2017-01-17 |
2020-09-30 |
Genentech, Inc. |
Subkutane her2-antikörperformulierungen
|
CA3050668C
(en)
|
2017-01-17 |
2023-08-15 |
Daiichi Sankyo Company, Limited |
Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
|
CN117180422A
(zh)
|
2017-03-02 |
2023-12-08 |
豪夫迈·罗氏有限公司 |
Her2阳性乳腺癌的辅助治疗
|
EP3615695A1
(de)
|
2017-04-24 |
2020-03-04 |
Genentech, Inc. |
Erbb2/her2-mutationen in der transmembran- oder juxtamembran-domäne
|
TWI794230B
(zh)
|
2017-05-15 |
2023-03-01 |
日商第一三共股份有限公司 |
抗cdh6抗體及抗cdh6抗體-藥物結合物、以及其製造方法
|
US11116827B2
(en)
|
2017-06-02 |
2021-09-14 |
Etubics Corporation |
Compositions and methods for tumor vaccination and immunotherapy involving HER antigens
|
WO2019044946A1
(ja)
|
2017-08-31 |
2019-03-07 |
第一三共株式会社 |
抗体-薬物コンジュゲートの新規製造方法
|
CN111051330A
(zh)
|
2017-08-31 |
2020-04-21 |
第一三共株式会社 |
抗体-药物缀合物的改进制备方法
|
CN117815404A
(zh)
|
2018-05-18 |
2024-04-05 |
第一三共株式会社 |
抗-muc1抗体-药物缀合物
|
CN115916834A
(zh)
|
2020-06-29 |
2023-04-04 |
基因泰克公司 |
帕妥珠单抗加曲妥珠单抗的固定剂量组合
|
EP4180061A1
(de)
|
2021-11-10 |
2023-05-17 |
Nerviano Medical Sciences S.r.l. |
Linker-reagenzien für anthracyclinderivate, antikörper-arznemittelkonjugate und verfahren
|
KR200497953Y1
(ko)
*
|
2021-12-06 |
2024-04-22 |
한국남동발전 주식회사 |
석탄 컨베이어 벨트 클리너 장치
|